MeSH term
Frequency | Condition_Probility | Acute Disease | 4 | 0.0 |
Adult | 29 | 0.0 |
Bone Marrow Transplantation/*statistics & numerical data | 4 | 4.0 |
Comparative Study | 34 | 0.0 |
Cord Blood Stem Cell Transplantation/*statistics & numerical data | 4 | 4.0 |
Fetal Blood/transplantation | 4 | 4.0 |
Humans | 317 | 0.0 |
Leukemia/*therapy | 4 | 3.0 |
Patient Selection | 4 | 2.0 |
Adolescent | 10 | 0.0 |
Aged | 17 | 0.0 |
Child | 7 | 0.0 |
Child, Preschool | 3 | 0.0 |
Female | 61 | 0.0 |
Infant | 2 | 0.0 |
Male | 39 | 0.0 |
Middle Aged | 22 | 0.0 |
Cardiac Output, Low/*mortality | 2 | 3.0 |
Coronary Arteriosclerosis/mortality | 2 | 3.0 |
Risk | 2 | 0.0 |
Surgical Procedures, Elective/*mortality | 2 | 3.0 |
Time Factors | 11 | 0.0 |
Aged, 80 and over | 5 | 0.0 |
Balloon Dilatation/adverse effects/*instrumentation | 3 | 7.0 |
Esophageal and Gastric Varices/therapy | 3 | 7.0 |
Esophagus/*injuries/radiography | 3 | 7.0 |
Fatal Outcome | 3 | 0.0 |
Foreign Bodies/*radiography | 3 | 7.0 |
Gastrointestinal Hemorrhage/therapy | 3 | 7.0 |
*Medical Errors | 3 | 6.0 |
Pleural Cavity/*radiography | 3 | 7.0 |
Tomography, X-Ray Computed | 3 | 0.0 |
Animals | 168 | 0.0 |
Antibodies, Monoclonal/chemistry | 2 | 2.0 |
Immunohistochemistry | 10 | 0.0 |
Prognosis | 3 | 0.0 |
Retrospective Studies | 2 | 0.0 |
Antigens, Surface/*immunology | 2 | 1.0 |
Bacterial Outer Membrane Proteins/*immunology | 2 | 8.0 |
Cell Separation | 3 | 0.0 |
Cells, Cultured | 73 | 0.0 |
*Drosophila Proteins | 133 | 11.0 |
Interleukins/metabolism | 2 | 6.0 |
Macrophages/immunology/metabolism | 2 | 4.0 |
Membrane Glycoproteins/genetics/*metabolism | 21 | 12.0 |
Mice | 118 | 0.0 |
Mice, Knockout | 44 | 1.0 |
Receptors, Cell Surface/genetics/*metabolism | 20 | 14.0 |
Research Support, Non-U.S. Gov't | 217 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 128 | 0.0 |
Signal Transduction | 39 | 0.0 |
Cell Line | 104 | 0.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Interleukin-6/biosynthesis | 6 | 2.0 |
Membrane Glycoproteins/*physiology | 41 | 15.0 |
Mice, Inbred C3H | 25 | 3.0 |
Receptors, Cell Surface/*physiology | 42 | 19.0 |
Transfection | 55 | 0.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 23 | 4.0 |
Acylation | 4 | 5.0 |
Crosses, Genetic | 2 | 0.0 |
Macrophages, Peritoneal/immunology/metabolism | 5 | 55.0 |
Membrane Glycoproteins/deficiency/genetics/metabolism/*physiology | 2 | 100.0 |
Mice, Inbred C57BL | 39 | 1.0 |
Molecular Weight | 2 | 0.0 |
Mycobacterium/*immunology | 3 | 16.0 |
Receptors, Cell Surface/deficiency/genetics/metabolism/*physiology | 2 | 100.0 |
Interleukin-1/metabolism | 4 | 1.0 |
Macrophages/metabolism | 6 | 1.0 |
Monocytes/metabolism | 4 | 1.0 |
RNA, Messenger/metabolism | 9 | 0.0 |
Up-Regulation | 14 | 0.0 |
Enzyme Activation/drug effects/immunology | 2 | 6.0 |
Lipopolysaccharides/*pharmacology | 23 | 5.0 |
Teichoic Acids/*pharmacology | 5 | 20.0 |
Infant, Newborn | 2 | 0.0 |
Lipid A/pharmacology | 5 | 25.0 |
Lymphocyte Activation | 8 | 0.0 |
Membrane Glycoproteins/*agonists | 4 | 66.0 |
Peptidoglycan/pharmacology | 12 | 75.0 |
Receptors, Cell Surface/*agonists | 4 | 44.0 |
Dose-Response Relationship, Drug | 13 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 5 | 0.0 |
Interleukin-6/biosynthesis/genetics | 2 | 5.0 |
Lipopolysaccharides/pharmacology | 42 | 4.0 |
Tumor Necrosis Factor-alpha/analysis/metabolism | 2 | 11.0 |
Drug Tolerance | 3 | 2.0 |
Endotoxins/*toxicity | 2 | 9.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*pharmacology | 2 | 1.0 |
Interferon Type II/*pharmacology | 4 | 0.0 |
Kinetics | 4 | 0.0 |
Lipopolysaccharides/*toxicity | 4 | 7.0 |
NF-kappa B/metabolism | 43 | 5.0 |
Tumor Necrosis Factor-alpha/genetics | 2 | 0.0 |
Amino Acid Sequence | 27 | 0.0 |
Base Sequence | 16 | 0.0 |
CpG Islands | 2 | 0.0 |
*Gene Expression Regulation | 6 | 0.0 |
Hela Cells | 9 | 0.0 |
Macrophages/*metabolism | 4 | 1.0 |
Membrane Glycoproteins/*genetics | 17 | 3.0 |
Molecular Sequence Data | 30 | 0.0 |
Monocytes/*metabolism | 2 | 0.0 |
Promoter Regions (Genetics) | 8 | 0.0 |
RNA, Messenger/analysis | 10 | 0.0 |
Receptors, Cell Surface/*genetics | 17 | 5.0 |
*Transcription, Genetic | 3 | 0.0 |
Actins/metabolism | 2 | 0.0 |
Antigens, CD14/*metabolism | 9 | 10.0 |
CHO Cells | 18 | 0.0 |
Cell Adhesion | 2 | 0.0 |
Hamsters | 23 | 0.0 |
Membrane Glycoproteins/*metabolism | 37 | 7.0 |
Receptors, Cell Surface/*metabolism | 38 | 6.0 |
Reverse Transcriptase Polymerase Chain Reaction | 25 | 0.0 |
Macrophage Activation/*immunology | 2 | 6.0 |
Membrane Glycoproteins/*immunology | 12 | 6.0 |
Receptors, Cell Surface/*immunology | 12 | 15.0 |
Signal Transduction/*immunology | 12 | 3.0 |
Binding Sites | 6 | 0.0 |
DNA Primers | 7 | 0.0 |
Peptidoglycan/*metabolism | 3 | 27.0 |
Polymerase Chain Reaction | 7 | 0.0 |
Recombinant Proteins/metabolism | 6 | 0.0 |
U937 Cells | 3 | 0.0 |
Antigens, CD14/genetics | 7 | 35.0 |
Antigens, Surface/genetics | 3 | 6.0 |
*Gene Expression Profiling | 2 | 0.0 |
Membrane Glycoproteins/*genetics/*metabolism | 2 | 8.0 |
RNA, Messenger/genetics/metabolism | 6 | 0.0 |
Receptors, Cell Surface/*genetics/*metabolism | 2 | 14.0 |
Receptors, Immunologic/genetics | 2 | 4.0 |
Cell Line, Tumor | 4 | 0.0 |
Membrane Glycoproteins/physiology | 6 | 3.0 |
Receptors, Cell Surface/physiology | 5 | 4.0 |
Cell Wall/immunology | 4 | 21.0 |
Interleukin-6/immunology | 3 | 10.0 |
Lipopolysaccharides/immunology | 11 | 9.0 |
NF-kappa B/immunology | 4 | 22.0 |
Peptidoglycan/immunology | 5 | 71.0 |
Teichoic Acids/immunology | 2 | 33.0 |
Up-Regulation/immunology | 5 | 3.0 |
Gene Deletion | 4 | 0.0 |
Gene Expression Regulation | 9 | 0.0 |
Mice, Inbred Strains | 2 | 0.0 |
Gene Expression Regulation/drug effects | 2 | 0.0 |
Cloning, Molecular | 6 | 0.0 |
JNK Mitogen-Activated Protein Kinases | 3 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 10 | 0.0 |
Mutagenesis, Site-Directed | 4 | 0.0 |
NF-kappa B/genetics/metabolism | 3 | 5.0 |
Tumor Cells, Cultured | 16 | 0.0 |
Lipopolysaccharides/metabolism | 7 | 6.0 |
Membrane Glycoproteins/metabolism | 6 | 1.0 |
Receptors, Cell Surface/metabolism | 7 | 1.0 |
*Adaptor Proteins, Signal Transducing | 3 | 0.0 |
Carrier Proteins/metabolism | 3 | 0.0 |
Cell Differentiation | 4 | 0.0 |
Immunity, Natural/*immunology | 3 | 15.0 |
*Intracellular Signaling Peptides and Proteins | 7 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 9 | 0.0 |
*Signal Transduction | 11 | 0.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 2 | 0.0 |
Interferon Type II/pharmacology | 3 | 0.0 |
Macrophage Activation/*physiology | 2 | 8.0 |
Membrane Glycoproteins/genetics/*physiology | 7 | 9.0 |
Receptors, Cell Surface/genetics/*physiology | 10 | 19.0 |
Antigens, CD/biosynthesis | 3 | 0.0 |
Biological Markers/analysis | 3 | 0.0 |
Gene Expression | 10 | 0.0 |
Membrane Glycoproteins/*biosynthesis/genetics | 7 | 12.0 |
NF-kappa B/biosynthesis | 2 | 13.0 |
Receptors, Cell Surface/*biosynthesis/genetics | 7 | 30.0 |
Interferon Type II/immunology | 2 | 2.0 |
Monocyte Chemoattractant Protein-1/immunology | 2 | 66.0 |
Cytokines/secretion | 2 | 2.0 |
Dendritic Cells/*immunology | 3 | 1.0 |
Flow Cytometry | 12 | 0.0 |
Gene Expression Profiling | 5 | 0.0 |
Lymphocyte Activation/immunology | 4 | 0.0 |
Lymphocyte Culture Test, Mixed | 3 | 0.0 |
Oligonucleotide Array Sequence Analysis | 3 | 0.0 |
Phenotype | 7 | 0.0 |
T-Lymphocytes/immunology | 5 | 0.0 |
Enzyme Activation | 6 | 0.0 |
Macrophages/drug effects/*metabolism | 2 | 3.0 |
Proto-Oncogene Proteins/metabolism | 2 | 0.0 |
Trans-Activators/metabolism | 3 | 0.0 |
p38 Mitogen-Activated Protein Kinases | 14 | 2.0 |
Antibodies, Monoclonal/pharmacology | 4 | 0.0 |
Antigens, CD14/immunology/metabolism | 4 | 30.0 |
Cytokines/*biosynthesis | 7 | 1.0 |
Down-Regulation/drug effects/immunology | 2 | 10.0 |
Membrane Glycoproteins/*immunology/metabolism | 3 | 18.0 |
Receptors, Cell Surface/*immunology/metabolism | 3 | 21.0 |
Signal Transduction/drug effects/immunology | 3 | 6.0 |
Antigens, CD14/physiology | 5 | 13.0 |
English Abstract | 4 | 0.0 |
Immunity, Natural | 13 | 5.0 |
Embryo | 2 | 0.0 |
Mitogen-Activated Protein Kinases/*physiology | 3 | 4.0 |
Phosphorylation | 12 | 0.0 |
Signal Transduction/drug effects/*physiology | 2 | 0.0 |
*Bacterial Proteins | 2 | 1.0 |
Blotting, Western | 5 | 0.0 |
DNA-Binding Proteins/metabolism | 6 | 0.0 |
Epithelial Cells/metabolism | 2 | 0.0 |
Glucocorticoids/*metabolism | 3 | 12.0 |
Haemophilus influenzae/*metabolism | 2 | 66.0 |
*I-kappa B | 3 | 1.0 |
MAP Kinase Signaling System | 4 | 1.0 |
Membrane Glycoproteins/*biosynthesis | 2 | 2.0 |
Mitogen-Activated Protein Kinases/*metabolism | 3 | 0.0 |
Models, Biological | 11 | 0.0 |
Porins/*metabolism | 2 | 66.0 |
Receptors, Cell Surface/*biosynthesis | 2 | 3.0 |
Interleukin-8/*biosynthesis | 2 | 3.0 |
RNA, Messenger/biosynthesis | 9 | 0.0 |
Mycobacterium tuberculosis/*immunology | 5 | 7.0 |
Receptors, Interleukin-1/*metabolism | 2 | 7.0 |
Signal Transduction/*physiology | 5 | 0.0 |
Active Transport, Cell Nucleus | 3 | 1.0 |
Antigens, CD/metabolism | 2 | 0.0 |
Antigens, Differentiation/genetics/*physiology | 3 | 18.0 |
Cell Nucleus/metabolism | 3 | 0.0 |
Membrane Glycoproteins/genetics/metabolism/*physiology | 2 | 18.0 |
Neisseria meningitidis/*immunology | 6 | 35.0 |
Antigens, CD14/*biosynthesis/genetics | 3 | 37.0 |
Cell Differentiation/drug effects | 3 | 0.0 |
Enzyme Inhibitors/pharmacology | 3 | 0.0 |
HL-60 Cells | 3 | 0.0 |
Trans-Activation (Genetics) | 6 | 0.0 |
Tumor Necrosis Factor-alpha/secretion | 3 | 2.0 |
Cytoplasm/*metabolism | 2 | 1.0 |
Escherichia coli | 2 | 0.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Staphylococcus aureus | 2 | 3.0 |
Antigens, CD14/metabolism | 10 | 8.0 |
Nitric Oxide/biosynthesis | 5 | 6.0 |
Species Specificity | 5 | 0.0 |
Escherichia coli/metabolism | 2 | 0.0 |
Immunoblotting | 4 | 0.0 |
Plasmids/metabolism | 4 | 0.0 |
Precipitin Tests | 5 | 0.0 |
Protein Binding | 10 | 0.0 |
Protein Kinases/metabolism | 6 | 1.0 |
Protein Structure, Tertiary | 12 | 0.0 |
Dendritic Cells/*physiology | 3 | 3.0 |
Mice, Inbred BALB C | 13 | 0.0 |
Antigens, Surface/physiology | 2 | 5.0 |
Inflammation Mediators/metabolism | 3 | 4.0 |
Macrophages/*immunology | 2 | 0.0 |
Models, Immunological | 4 | 1.0 |
DNA-Binding Proteins/physiology | 2 | 0.0 |
Genetic Vectors | 2 | 0.0 |
Interleukin-8/genetics | 4 | 7.0 |
Promoter Regions (Genetics)/*genetics | 2 | 0.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
Dimerization | 6 | 0.0 |
Membrane Glycoproteins/*chemistry | 2 | 6.0 |
Receptors, Cell Surface/*chemistry | 2 | 20.0 |
Antigens, CD14/biosynthesis | 7 | 11.0 |
Cytokines/biosynthesis | 14 | 2.0 |
Liver/metabolism | 2 | 0.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Genes, Reporter | 7 | 0.0 |
Ligands | 18 | 0.0 |
Rats | 3 | 0.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Tumor Necrosis Factor-alpha/*metabolism | 3 | 0.0 |
Signal Transduction/genetics/*immunology | 8 | 9.0 |
Bacterial Proteins/*immunology | 3 | 10.0 |
Epithelial Cells/*immunology | 2 | 10.0 |
Interleukin-8/biosynthesis | 8 | 7.0 |
Membrane Glycoproteins/antagonists & inhibitors/*metabolism | 2 | 33.0 |
Oligopeptides/immunology | 2 | 11.0 |
Receptors, Cell Surface/antagonists & inhibitors/*metabolism | 2 | 40.0 |
Gram-Negative Bacteria/*immunology | 3 | 23.0 |
Gram-Positive Bacteria/*immunology | 3 | 33.0 |
Trans-Activation (Genetics)/immunology | 3 | 12.0 |
*Macrophage Activation | 2 | 3.0 |
*Immunity, Natural | 6 | 10.0 |
Escherichia coli/*pathogenicity | 3 | 17.0 |
Membrane Glycoproteins/analysis/physiology | 2 | 28.0 |
Porphyromonas gingivalis/*pathogenicity | 2 | 33.0 |
Receptors, Cell Surface/analysis/physiology | 2 | 100.0 |
NF-kappa B/*metabolism | 10 | 1.0 |
Chromatography, High Pressure Liquid | 3 | 0.0 |
Genetic Predisposition to Disease | 4 | 0.0 |
Polymorphism, Genetic | 3 | 0.0 |
Risk Factors | 3 | 0.0 |
Macrophages/cytology/metabolism | 2 | 8.0 |
Mutation | 5 | 0.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
Signal Transduction/physiology | 11 | 1.0 |
Antibodies/immunology | 2 | 0.0 |
Biological Markers | 2 | 0.0 |
Lipopolysaccharides/immunology/pharmacology | 2 | 9.0 |
Oligodeoxyribonucleotides/immunology | 2 | 33.0 |
Staphylococcus aureus/immunology | 2 | 1.0 |
Antigens, Differentiation/physiology | 7 | 13.0 |
Lipopolysaccharides | 3 | 2.0 |
*Receptors, Immunologic | 12 | 7.0 |
*Apoptosis | 2 | 0.0 |
Culture Media | 2 | 0.0 |
Kidney | 2 | 0.0 |
Luciferases/analysis | 2 | 16.0 |
Membrane Glycoproteins/deficiency/genetics/*physiology | 3 | 20.0 |
Microscopy, Confocal | 3 | 0.0 |
NF-kappa B/physiology | 6 | 6.0 |
Receptors, Cell Surface/deficiency/genetics/*physiology | 3 | 20.0 |
Specific Pathogen-Free Organisms | 2 | 2.0 |
Transcription, Genetic | 4 | 0.0 |
Signal Transduction/drug effects | 4 | 0.0 |
Membrane Glycoproteins/chemistry/genetics/*metabolism | 2 | 8.0 |
Mutagenesis | 2 | 0.0 |
Staphylococcus aureus/*metabolism | 2 | 8.0 |
In Vitro | 12 | 0.0 |
Leukocytes, Mononuclear/immunology | 2 | 0.0 |
Lipopolysaccharides/*immunology | 5 | 6.0 |
Membrane Glycoproteins/genetics/*immunology | 7 | 13.0 |
Receptors, Cell Surface/genetics/*immunology | 9 | 39.0 |
Structure-Activity Relationship | 5 | 0.0 |
Monocytes/immunology | 6 | 1.0 |
Immunity, Cellular | 5 | 0.0 |
*Acute-Phase Proteins | 4 | 2.0 |
Antigens, CD14/*physiology | 5 | 10.0 |
Carrier Proteins/*physiology | 2 | 0.0 |
Polymyxin B/pharmacology | 4 | 7.0 |
Antigens, Bacterial/*immunology | 3 | 2.0 |
Antigens, Surface/biosynthesis/genetics | 2 | 18.0 |
Clone Cells | 2 | 0.0 |
*Immune Tolerance/genetics | 2 | 40.0 |
Lipopolysaccharides/antagonists & inhibitors/*immunology | 2 | 66.0 |
NF-kappa B/antagonists & inhibitors/metabolism | 2 | 6.0 |
Leukocytes, Mononuclear/immunology/metabolism | 2 | 4.0 |
Membrane Glycoproteins/chemistry/*genetics | 2 | 5.0 |
Receptors, Cell Surface/chemistry/*genetics | 2 | 9.0 |
Sequence Alignment | 5 | 0.0 |
NF-kappa B/immunology/metabolism | 2 | 40.0 |
Membrane Glycoproteins/*analysis | 4 | 2.0 |
Receptors, Cell Surface/*analysis | 4 | 3.0 |
Membrane Glycoproteins/genetics/immunology/*metabolism | 3 | 21.0 |
Receptors, Cell Surface/genetics/immunology/*metabolism | 3 | 30.0 |
TNF Receptor-Associated Factor 6 | 7 | 5.0 |
Apoptosis/*drug effects | 3 | 0.0 |
Neutrophils/*physiology | 2 | 1.0 |
Bronchi/cytology | 2 | 7.0 |
Virulence | 2 | 0.0 |
Adjuvants, Immunologic/*pharmacology | 3 | 1.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 2 | 0.0 |
Mitogen-Activated Protein Kinase 3 | 3 | 0.0 |
Trans-Activators/*metabolism | 2 | 0.0 |
Transcription Factor AP-1/metabolism | 3 | 1.0 |
Antibodies, Monoclonal/metabolism/pharmacology | 2 | 9.0 |
Bacterial Proteins/*metabolism | 2 | 4.0 |
Monocytes/drug effects/immunology/metabolism | 2 | 10.0 |
Macrophages/immunology | 6 | 2.0 |
Signal Transduction/immunology | 10 | 3.0 |
Solubility | 6 | 0.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 2 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 2 | 0.0 |
Interleukin-12/biosynthesis | 4 | 4.0 |
Lipoproteins/*immunology | 2 | 11.0 |
Proteins/physiology | 3 | 2.0 |
Receptors, Interleukin-1/*physiology | 3 | 21.0 |
Antigens, CD14/immunology | 2 | 3.0 |
Cytokines/*biosynthesis/genetics | 3 | 4.0 |
Interleukin-1/biosynthesis/genetics | 2 | 7.0 |
Interleukin-8/biosynthesis/genetics | 4 | 16.0 |
Intracellular Fluid/immunology | 2 | 13.0 |
Tumor Necrosis Factor-alpha/biosynthesis/genetics | 2 | 3.0 |
Lipopolysaccharides/*metabolism | 2 | 1.0 |
Superoxides/metabolism | 3 | 1.0 |
Dendritic Cells/immunology | 4 | 2.0 |
Gene Expression Regulation/immunology | 7 | 4.0 |
Lipoproteins/*pharmacology | 2 | 4.0 |
Mycoplasma fermentans/*pathogenicity | 2 | 100.0 |
Caco-2 Cells | 2 | 0.0 |
Down-Regulation/genetics/immunology | 3 | 10.0 |
Membrane Glycoproteins/*biosynthesis/physiology | 2 | 22.0 |
Receptors, Cell Surface/*biosynthesis/physiology | 2 | 40.0 |
Protein-Serine-Threonine Kinases/physiology | 3 | 3.0 |
Receptors, Interleukin-1/physiology | 2 | 20.0 |
United States | 2 | 0.0 |
Case-Control Studies | 4 | 0.0 |
Inflammation/immunology | 4 | 3.0 |
Interleukin-10/biosynthesis | 5 | 4.0 |
Monocytes/*immunology | 3 | 0.0 |
Gene Expression Regulation/*drug effects | 3 | 0.0 |
Macrophages/*drug effects/metabolism | 2 | 5.0 |
NF-kappa B/*physiology | 3 | 3.0 |
Peptidoglycan/*pharmacology | 3 | 50.0 |
Lipoproteins/immunology | 2 | 18.0 |
Antigens, Differentiation/*physiology | 3 | 3.0 |
*Immune Tolerance | 3 | 1.0 |
Promoter Regions (Genetics)/immunology | 2 | 2.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Bacterial Proteins/immunology | 2 | 9.0 |
Macrophage Activation | 4 | 2.0 |
Antigens, Surface/*physiology | 2 | 3.0 |
Amino Acid Motifs | 2 | 0.0 |
Macrophages, Peritoneal/immunology | 2 | 28.0 |
Immunophenotyping | 2 | 0.0 |
Mycobacterium tuberculosis/immunology | 4 | 13.0 |
Cell Line, Transformed | 2 | 0.0 |
Drug Synergism | 4 | 0.0 |
Lipoproteins/pharmacology | 5 | 22.0 |
Tumor Necrosis Factor-alpha/pharmacology | 3 | 0.0 |
Membrane Glycoproteins/biosynthesis/genetics/metabolism/*physiology | 3 | 75.0 |
Receptors, Cell Surface/biosynthesis/genetics/metabolism/*physiology | 3 | 75.0 |
Bacterial Infections/*immunology | 3 | 9.0 |
Sequence Homology, Amino Acid | 5 | 0.0 |
Pregnancy | 2 | 0.0 |
RNA, Messenger/genetics | 4 | 0.0 |
Interleukin-1/pharmacology | 3 | 0.0 |
Mycobacterium avium/*immunology | 2 | 22.0 |
Up-Regulation/genetics/immunology | 4 | 7.0 |
Antigen Presentation | 2 | 0.0 |
Tumor Necrosis Factor-alpha/physiology | 2 | 1.0 |
Crystallography, X-Ray | 3 | 0.0 |
Models, Molecular | 4 | 0.0 |
Point Mutation | 4 | 0.0 |
Protein Conformation | 2 | 0.0 |
Antigens, CD14/biosynthesis/genetics | 3 | 42.0 |
Membrane Glycoproteins/biosynthesis/genetics | 2 | 4.0 |
Receptors, Cell Surface/biosynthesis/genetics | 2 | 9.0 |
*Gene Expression Regulation/immunology | 2 | 22.0 |
Receptors, Cell Surface/immunology | 4 | 11.0 |
Receptors, Interleukin-1/*immunology | 2 | 40.0 |
*Polymorphism, Genetic | 6 | 0.0 |
Interleukin-12/*biosynthesis | 3 | 8.0 |
Monocytes/immunology/metabolism | 2 | 4.0 |
Lipopolysaccharides/chemistry/*metabolism | 2 | 28.0 |
Apoptosis/*physiology | 2 | 0.0 |
Caspases/metabolism | 2 | 0.0 |
Interleukin-18/biosynthesis | 2 | 33.0 |
Membrane Glycoproteins/deficiency/genetics/physiology | 2 | 50.0 |
Receptors, Cell Surface/deficiency/genetics/physiology | 2 | 66.0 |
Membrane Glycoproteins/metabolism/*physiology | 3 | 12.0 |
Receptors, Cell Surface/metabolism/*physiology | 3 | 15.0 |
Receptors, Interleukin-1/metabolism | 2 | 8.0 |
Epithelial Cells/cytology/immunology/*metabolism | 2 | 50.0 |
Interleukin-6/metabolism | 4 | 1.0 |
Interleukin-8/metabolism | 2 | 1.0 |
Protein Kinase C/*physiology | 2 | 2.0 |
Dose-Response Relationship, Immunologic | 3 | 0.0 |
Heat | 2 | 0.0 |
Membrane Glycoproteins/immunology/*physiology | 2 | 11.0 |
Receptors, Cell Surface/immunology/*physiology | 2 | 13.0 |
Membrane Glycoproteins/biosynthesis/deficiency/genetics/*physiology | 3 | 100.0 |
Receptors, Cell Surface/biosynthesis/deficiency/genetics/*physiology | 4 | 100.0 |
Carrier Proteins/genetics/*metabolism | 2 | 0.0 |
Genotype | 3 | 0.0 |
Inflammation Mediators/*metabolism | 2 | 3.0 |
Carrier Proteins/physiology | 5 | 4.0 |
Lipopolysaccharides/metabolism/pharmacology | 2 | 11.0 |
B-Lymphocytes/immunology | 2 | 0.0 |
Protein Biosynthesis | 3 | 0.0 |
NF-kappa B/biosynthesis/metabolism | 2 | 50.0 |
Sequence Deletion | 5 | 0.0 |
Analysis of Variance | 2 | 0.0 |
Flagellin/pharmacology | 2 | 28.0 |
Interleukin-8/immunology | 2 | 20.0 |
Zymosan/pharmacology | 3 | 3.0 |
Luciferases/genetics | 3 | 0.0 |
Signal Transduction/genetics/immunology | 3 | 3.0 |
*Gene Expression Regulation, Viral | 2 | 0.0 |
Antigens, Differentiation/metabolism | 2 | 1.0 |
Monocytes/drug effects/*metabolism | 2 | 1.0 |
Signal Transduction/*drug effects | 2 | 0.0 |
Gene Frequency/genetics | 3 | 0.0 |
Genetic Predisposition to Disease/genetics | 2 | 0.0 |
Cytokines/metabolism | 5 | 1.0 |
Immunization | 2 | 0.0 |
Gene Expression/immunology | 2 | 2.0 |
Staphylococcus aureus/pathogenicity | 2 | 66.0 |
Gene Expression Regulation/*physiology | 3 | 0.0 |
Membrane Glycoproteins/drug effects/*metabolism | 2 | 33.0 |
Receptors, Cell Surface/drug effects/*metabolism | 2 | 4.0 |
Heterozygote | 3 | 0.0 |
Polymorphism, Single Nucleotide/*genetics | 2 | 0.0 |
Lipid A/*analogs & derivatives/pharmacology | 2 | 10.0 |
Macromolecular Substances | 2 | 0.0 |
Receptors, Immunologic/physiology | 5 | 4.0 |
Umbilical Veins/cytology | 2 | 0.0 |
Receptors, Immunologic/deficiency/genetics/*physiology | 2 | 50.0 |
Receptors, Cell Surface/genetics | 2 | 1.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 2 | 0.0 |
Phagocytosis | 2 | 0.0 |
Statistics, Nonparametric | 2 | 0.0 |
Neutrophils/immunology | 2 | 1.0 |
Body Mass Index | 2 | 0.0 |
Escherichia coli/immunology | 2 | 2.0 |
Cell Membrane/immunology | 2 | 0.0 |
Phagocytosis/immunology | 2 | 3.0 |
Endotoxins/pharmacology | 2 | 2.0 |
Membrane Glycoproteins/immunology | 3 | 1.0 |
Alleles | 3 | 0.0 |
Asthma/*immunology | 2 | 2.0 |
Chi-Square Distribution | 2 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Antigen-Presenting Cells/immunology | 2 | 0.0 |
Gene Frequency | 2 | 0.0 |
Immunity, Natural/immunology | 2 | 8.0 |
Luciferases/metabolism | 2 | 0.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Membrane Glycoproteins/genetics | 2 | 1.0 |
*Genetic Predisposition to Disease | 3 | 0.0 |
Cysteine/*analogs & derivatives/pharmacology | 2 | 28.0 |
Dendritic Cells/*immunology/metabolism | 2 | 4.0 |
Down-Regulation/genetics/*immunology | 2 | 10.0 |
Down-Regulation | 3 | 0.0 |
*Down-Regulation | 2 | 0.0 |
Macrophages, Peritoneal | 2 | 100.0 |
Genetic Complementation Test | 2 | 0.0 |
Microscopy, Fluorescence | 2 | 0.0 |
Macrophages/immunology/*metabolism | 2 | 6.0 |
Antigens, Surface/metabolism | 2 | 1.0 |
Gram-Negative Bacteria/immunology | 2 | 15.0 |
Gram-Positive Bacteria/immunology | 2 | 40.0 |
Sequence Homology | 2 | 0.0 |
Cattle | 2 | 0.0 |
Down-Regulation/physiology | 2 | 2.0 |
Recombinant Fusion Proteins/physiology | 2 | 0.0 |
Signal Transduction/drug effects/*immunology | 2 | 5.0 |
Immune Tolerance | 2 | 0.0 |
Mice, Transgenic | 4 | 0.0 |
Respiratory Mucosa/*cytology/metabolism | 2 | 40.0 |
Adjuvants, Immunologic | 2 | 3.0 |
Antigens, Differentiation/genetics/*metabolism | 2 | 8.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
Receptors, Immunologic/genetics/*metabolism | 2 | 5.0 |
Neutrophils/*immunology | 2 | 1.0 |
Antibodies, Monoclonal/immunology | 2 | 0.0 |
Membrane Glycoproteins/immunology/*metabolism | 3 | 7.0 |
NF-kappa B/antagonists & inhibitors/*metabolism | 2 | 3.0 |
Receptors, Cell Surface/immunology/*metabolism | 3 | 9.0 |
In Situ Hybridization | 2 | 0.0 |
Cytokines/*metabolism | 3 | 1.0 |
Receptors, Interleukin-1/chemistry/genetics/*metabolism | 2 | 100.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Membrane Glycoproteins/antagonists & inhibitors/genetics/*metabolism | 2 | 40.0 |
Receptors, Cell Surface/antagonists & inhibitors/genetics/*metabolism | 2 | 40.0 |
Tumor Necrosis Factor-alpha/metabolism | 4 | 0.0 |
Candida albicans/immunology | 2 | 4.0 |
Cell Adhesion Molecules/biosynthesis | 2 | 2.0 |
Cell Survival/drug effects | 2 | 0.0 |
Cytokines/physiology | 2 | 1.0 |
Mitogen-Activated Protein Kinases/physiology | 2 | 1.0 |
Receptors, Immunologic/*physiology | 2 | 1.0 |
Lipoproteins/*metabolism | 2 | 1.0 |
Interleukin-8/secretion | 2 | 5.0 |
Teichoic Acids/pharmacology | 4 | 30.0 |
Tumor Necrosis Factor-alpha/genetics/metabolism | 2 | 3.0 |
Up-Regulation/physiology | 2 | 1.0 |
Injections, Intraperitoneal | 2 | 1.0 |
N-Formylmethionine Leucyl-Phenylalanine/pharmacology | 2 | 0.0 |
Antibody Specificity | 2 | 0.0 |
CpG Islands/immunology | 2 | 15.0 |
Interleukin-8/*metabolism | 2 | 3.0 |
Disease Models, Animal | 2 | 0.0 |
Chronic Disease | 2 | 0.0 |
Immunoenzyme Techniques | 3 | 0.0 |
Electrophoretic Mobility Shift Assay | 2 | 0.0 |
Membrane Glycoproteins/drug effects/*physiology | 2 | 50.0 |
Neutrophil Activation/*physiology | 2 | 13.0 |
Membrane Glycoproteins/analysis/*physiology | 2 | 22.0 |
Receptors, Cell Surface/analysis/*physiology | 2 | 18.0 |
Monocytes | 2 | 2.0 |
Macrophages/cytology/*metabolism | 2 | 10.0 |
Substrate Specificity | 2 | 0.0 |
